ORLISTAT | N020766 | CHEPLAPHARM ARZNEIMITTEL GMBH
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Public Citizen's Health Research Group - Ctitizen Petition FDA-2011-P-0297 · 4 docket documents Public Citizen's Health Research Group, represented by Michael Carome, filed a citizen petition pursuant to 21 U.S.C. Section 355(e)(3) requesting that the FDA immediately ban both the prescription drug Xenical (orlistat) and the over-the-counter drug Alli (orlistat) because they expose patients to | Other | 2011-05-05 | Denied | — |
Public Citizen FDA-2006-P-0326 · 6 docket documents Public Citizen filed this petition pursuant to 21 U.S.C. Section 355(e)(3) requesting that the FDA immediately remove prescription Xenical (orlistat) from the market because the drug causes a significant increase in aberrant crypt foci in rat colons, which are believed to be precursors to colon canc | 505(q) | 2009-04-23 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$6.93
per ea
Lowest NADAC/Unit
$4.61
per ea
Brand NDCs
1
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 61269056590ORLISTAT 120 MG CAPSULE | $6.93 | EA | Generic | — | 2026-06-17 |
| 61269046090XENICAL 120 MG CAPSULE | $4.61 | EA | Brand | $6.93 | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.